Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 11Terminated 5Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 2Breast Neoplasms 2Sarcoma 1Lymphoma, T-Cell 1Hematologic Neoplasms 1

Interventions

Injections 3Doxorubicin 3anlotinib 2toripalimab 1pemigatinib 1pazopanib 1montelukast 1liposomal doxorubicin 1eribulin 1chlorhexidine gluconate 1camrelizumab 1bexmarilimab 1apatinib 1X-Rays 1Trabectedin 1Temozolomide 1Tablets 1Sodium Chloride 1Radiotherapy 1Proton Therapy 1Positron Emission Tomography Computed Tomography 1Nivolumab 1Negative-Pressure Wound Therapy 1KP 1339 1Ipilimumab 1Immunotherapy 1Heavy Ion Radiotherapy 1Granulocyte Colony-Stimulating Factor 1Epirubicin 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Sarcoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT07602777 2026-05-22

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

GlaxoSmithKline

Phase 1/2 Not yet recruiting
113 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡